Brunei Chinese chamber of commerce holds event on traditional Chinese medicine
According to the See Hua Daily News on Friday, the event aimed to enhance mutual understanding between civil organisations in Brunei and China and explore future collaboration opportunities in traditional Chinese medicine research and the health industry. - Xinhua
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
Zambia launches portable digital x-rays guidelines
LUSAKA, July 22 (Xinhua) -- Zambia on Tuesday launched national operational guidelines for the use of portable digital X-ray units to enhance diagnostic services across the country. Kennedy Lishimpi, permanent secretary for technical services at the Ministry of Health, said the lack of standardized national guidelines has led to inconsistencies in usage, safety protocols, and regulatory compliance. "These guidelines will ensure that the use of portable x-ray technology aligns with national policy, global best practices, and safety standards, while enhancing efficiency across health facilities," Lishimpi said at the launch. He noted that with the increasing demand for flexible and rapid diagnostic imaging solutions, portable digital X-ray units have become a game-changer, particularly in the management of tuberculosis, trauma, and other critical conditions. According to Lishimpi, the introduction of the new guidelines will facilitate the broader use of portable digital X-ray units, promoting more equitable access to diagnostic services throughout the country. He called for the full implementation and integration of the guidelines into national health systems to ensure all Zambians can benefit. The government, he emphasized, remains committed to improving access to quality diagnostic services at all levels of care, especially in hard-to-reach and underserved communities.
Hype Malaysia
11 hours ago
- Hype Malaysia
Chinese Tourist Stunned By RM1 Injury Treatment At Malaysian Government Clinic
As Malaysians living in Malaysia, we are incredibly fortunate to be able to have various options when it comes to our healthcare. In case private clinics aren't within your price range, government-owned clinics offer top-notch service with a shocking price tag. Detailing his experience to Xiaohongshu, a Chinese national tells about his encounter at a Malaysian government clinic where he was able to get treatment for a minor injury for just RM1. He recounts that he had cut his thumb on a vegetable slicer, which prompted it to bleed nonstop and to seek medical assistance fast. The man explained that he was admittedly nervous to receive a hefty bill, but was later proved wrong as medical staff helped him with care and even pointed out how cute and neat the nurse had bandaged his wound. Explaining further in the comments section, the man explained that his wife was a Malaysian citizen, making him eligible for public healthcare. 'Even though the fees are low, the staff never cut corners. They give their best and treat everyone equally', the man added in his post. He also noted that this was not his first time at a government clinic, but expressed that every time he went, he felt warmth and peace of mind. Have you ever sought medical attention at a government clinic? Source: Xiaohongshu Alyssa Gabrielle contributed to this article
Malaysian Reserve
12 hours ago
- Malaysian Reserve
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ — METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs). Founded in 1978, the Controlled Release Society is the world's foremost nonprofit scientific organization dedicated to advanced drug delivery. At this year's meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS and a Member of the U.S. National Academy of Engineering, together with Dr. Andong Liu, Vice President of METiS, presented the poster titled: 'AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery.' The AiLNP platform is METiS' proprietary AI-driven system for nucleic acid delivery design. It integrates a de novo lipid generation foundation model, a high-throughput microfluidics-based LNP assembly and screening system, and a large-scale, proprietary lipid library. Collectively, these innovations expand the design space of nanomaterials by over 1,000-fold compared to conventional approaches—effectively overcoming long-standing discovery bottlenecks in the field. By combining predictive AI models with molecular dynamics simulations, the AiLNP platform provides mechanistic insights into lipid behavior and enables prediction of more than 10 physicochemical parameters. It further allows for rational design and optimization of LNP components and ratios to construct customized, high-performance delivery systems. Key findings from the poster highlight the platform's ability to accelerate LNP design cycles while significantly improving discovery speed and quality across multiple tissue targets: Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction in serum TTR levels with only a transient, mild elevation in liver enzymes. Lung-targeted LNPs exhibited high delivery efficiency and specificity in rodents, with successful translation to NHPs. At the cellular level, these LNPs transfected a broad range of pulmonary cell types in NHPs—including stem-like cells, alveolar type II cells (>30%), and airway basal cells (>10%) at 1 mg/kg—supporting their potential for durable genetic correction. METiS' Musle-targeted LNPs also enabled successful in vivo delivery and gene editing in multiple types of muscle cells in mice. 'This year's CRS theme, 'Next-Generation Delivery Innovation', reflects the rapid evolution in drug delivery technologies. Among the 410 accepted posters across 12 research tracks, more than 200 focused on nanomedicine, nanodelivery, and gene editing—demonstrating these as the most active areas of exploration,' said Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS Technologies. 'We're pleased to present our findings at the world's premier scientific forum for drug delivery and remain committed to pushing the boundaries of LNP discovery.' Dr. Chris Lai, Co-founder and CEO of METiS, added: 'Since day one, METiS has been positioning at the global forefront of AI-powered nanomaterial innovation. We believe nanodelivery is the critical enabler of the next generation of programmable medicines—and that AI will be the key catalyst driving this transformation.' AI Nanodelivery for a Healthier Future. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design. METiS' platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives.
